Cargando…
Immunotoxin – a new treatment option in patients with relapsed and refractory Hodgkin lymphoma
BACKGROUND: Even though Hodgkin lymphoma is a highly curable disease, some of the patients have either a refractory disease or experience a relapse following a successful primary therapy. Durable responses and remissions in patients with relapsed or refractory disease may be achieved in approximatel...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Versita, Warsaw
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722920/ https://www.ncbi.nlm.nih.gov/pubmed/26834516 http://dx.doi.org/10.1515/raon-2015-0036 |